Investors in Novo Nordisk (CPSE:NOVO B) have just gotten a major jolt with fresh data from the STEER real-world study, presented at the European Society of Cardiology Congress 2025. The company’s obesity drug Wegovy showed a strikingly greater reduction in risk for serious cardiovascular events compared to tirzepatide, among people living with obesity and established cardiovascular disease but no diabetes. With a 57% greater risk reduction for heart attack, stroke, and deaths from any cause...
Sydbank announced results for the half year ended June 30, 2025, reporting net interest income of DKK 1,930 million and net income of DKK 1,207 million, both lower than the previous year, while also completing a share buyback program totaling 1,138,104 shares for DKK 490 million.
The bank also issued new profit after tax guidance for 2025, forecasting annual earnings between DKK 2,200 million and DKK 2,600 million, giving investors a fresh outlook for the year.
With these updates, we'll...
On August 26, 2025, Genmab announced that the U.S. FDA granted Breakthrough Therapy Designation to its investigational antibody-drug conjugate Rina-S for adult patients with recurrent or progressive endometrial cancer who progressed after prior platinum-based and PD-(L)1 therapies.
This regulatory milestone spotlights Rina-S as a leading late-stage asset within Genmab's expanding oncology portfolio, reflecting the growing recognition of its promise in difficult-to-treat cancers.
We'll...
Amid concerns over the independence of the U.S. Federal Reserve and political uncertainties in Europe, the pan-European STOXX Europe 600 Index recently ended lower, reflecting broader market apprehensions. For investors looking beyond well-known stocks, penny stocks—often associated with smaller or newer companies—remain an intriguing area of exploration. Despite being considered a somewhat outdated term, these stocks can still offer compelling opportunities when backed by strong financials...
